Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 1/20 | 0.37 |
| ▸ | IL6 | P05231 | 3/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159200 | 0.86 | EGLN1 (0.45) | EGLN1MLNRHTTHCRTR1HCRTR2 | |
| SCHEMBL6165921 | 0.83 | EGLN1 (0.43) | EGLN1LMNAMAPK1MLNRIL6 | |
| SCHEMBL6162322 | 0.74 | EGLN1 (0.45) | EGLN1MLNRHTTHCRTR1HCRTR2 | |
| SCHEMBL6161048 | 0.74 | EGLN1 (0.45) | EGLN1MLNRHTTHCRTR1HCRTR2 | |
| SCHEMBL6160758 | 0.73 | EGLN1 (0.51) | EGLN1MLNRHTTHCRTR1HCRTR2 | |
| SCHEMBL6160356 | 0.73 | EGLN1 (0.46) | EGLN1MLNRHTTHCRTR1HCRTR2 | |
| SCHEMBL6161683 | 0.73 | HTT (0.48) | EGLN1LMNAMLNRHTTHCRTR1 | |
| SCHEMBL6161160 | 0.72 | EGLN1 (0.46) | EGLN1MLNRHTTHCRTR1HCRTR2 | |
| SCHEMBL6163042 | 0.72 | EGLN1 (0.48) | EGLN1MLNRHTT | |
| SCHEMBL6162291 | 0.72 | EGLN1 (0.49) | EGLN1MLNRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. | 2005-07-28 | — | — | US | claimed |
| EP-1500658-A1 | NOVEL THIOL DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | claimed |
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1500658-A1 | NOVEL THIOL DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TST, QSOX1, MMP1 | EGLN1 841/4885LMNA 4326/4885MAPK1 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.